Equities research analysts expect Spero Therapeutics Inc (NASDAQ:SPRO) to post ($0.89) earnings per share for the current quarter, according to Zacks. Three analysts have made estimates for Spero Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.87) and the lowest estimate coming in at ($0.92). Spero Therapeutics posted earnings of ($0.60) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 48.3%. The business is scheduled to report its next earnings report on Thursday, November 14th.
On average, analysts expect that Spero Therapeutics will report full-year earnings of ($2.94) per share for the current fiscal year, with EPS estimates ranging from ($3.55) to ($2.12). For the next year, analysts expect that the company will post earnings of ($3.42) per share, with EPS estimates ranging from ($4.11) to ($2.82). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last issued its earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). The business had revenue of $2.16 million for the quarter, compared to the consensus estimate of $6.95 million. Spero Therapeutics had a negative net margin of 321.37% and a negative return on equity of 33.84%.
Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its position in Spero Therapeutics by 56.0% during the second quarter. BlackRock Inc. now owns 656,778 shares of the company’s stock valued at $7,559,000 after buying an additional 235,691 shares during the period. AWM Investment Company Inc. boosted its position in Spero Therapeutics by 6.4% during the second quarter. AWM Investment Company Inc. now owns 598,315 shares of the company’s stock valued at $6,887,000 after buying an additional 36,019 shares during the period. Novo Holdings A S purchased a new stake in Spero Therapeutics during the second quarter valued at about $5,363,000. Vanguard Group Inc. boosted its position in Spero Therapeutics by 4.5% during the second quarter. Vanguard Group Inc. now owns 437,204 shares of the company’s stock valued at $5,032,000 after buying an additional 18,814 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Spero Therapeutics by 89.7% during the second quarter. Renaissance Technologies LLC now owns 214,903 shares of the company’s stock valued at $2,474,000 after buying an additional 101,600 shares during the period. Institutional investors and hedge funds own 45.08% of the company’s stock.
Shares of SPRO traded up $0.22 during mid-day trading on Thursday, reaching $10.00. 4,147 shares of the stock traded hands, compared to its average volume of 30,021. The firm has a fifty day moving average price of $10.29 and a 200 day moving average price of $11.52. The company has a market cap of $182.50 million, a price-to-earnings ratio of -3.85 and a beta of 2.08. The company has a current ratio of 13.66, a quick ratio of 13.66 and a debt-to-equity ratio of 0.04. Spero Therapeutics has a 1 year low of $5.52 and a 1 year high of $14.48.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Read More: Candlestick
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.